• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cel-Sci Corp (NY: CVM )

    0.5958 -0.0087 (-1.44%)
    Official Closing Price Updated: 8:00 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 308,217
    Open 0.6045
    Bid (Size) 0.5902 (1)
    Ask (Size) 0.6499 (5)
    Prev. Close 0.6045
    Today's Range 0.5800 - 0.6045
    52wk Range 0.5402 - 3.230
    Shares Outstanding 61,493,229
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
    From CEL-SCI Corporation
    Via Business Wire
    FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
    From CEL-SCI Corporation
    Via Business Wire

    Performance

    YTD
    -77.85%
    -77.85%
    1 Month
    -34.91%
    -34.91%
    3 Month
    -46.80%
    -46.80%
    6 Month
    -51.56%
    -51.56%
    1 Year
    -76.36%
    -76.36%

    More News

    Read More
    CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
    From CEL-SCI Corporation
    Via Business Wire
    CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024
    Via InvestorPlace
    CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
    From CEL-SCI Corporation
    Via Business Wire
    The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
    From CEL-SCI Corporation
    Via Business Wire
    CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024
    Via InvestorPlace
    CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
    From CEL-SCI Corporation
    Via Business Wire
    BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering
    Via Investor Brand Network
    Exposures Product Safety
    CEL-SCI Announces Closing of $10.8 Million Offering
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Announces Pricing of $10.8 Million Offering
    From CEL-SCI Corporation
    Via Business Wire
    Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Appoints Robert Watson as Chairperson of the Board
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
    From CEL-SCI Corporation
    Via Business Wire
    Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
    From CEL-SCI Corporation
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why CEL-SCI (CVM) Shares Are Trading Higher
    Via Benzinga
    Exposures Product Safety
    CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
    From CEL-SCI Corporation
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    CEL-SCI Appoints Mario Gobbo to Its Board of Directors
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Corporation Issues Letter to Shareholders
    From CEL-SCI Corporation
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.